Table 8.
Clinical trials underway to evaluate the effectiveness of immunotherapy for brain metastases.
| Trial No. | Tumor Type | Phase | Drugs | n | Trial Arm | Country | Principle Institute | Duration |
|---|---|---|---|---|---|---|---|---|
| NCT 02460068 | Melanoma | III | Nivolumab Ipilimumab | 168 | (1) Ipilimumab + Fotemustine; (2) Ipilimumab + Nivolumab; (3) Bevaczumab + Pembrolizumab; (4) Fortemustine |
USA | University Hospital of Siena |
2012–2020 |
| NCT 02681549 | Melanoma NSCLC | II | Pembrolizumab | 53 | Pembrolizumab + Bevacizumab |
USA | Yale University | 2016–2024 |
| NCT 02696993 | NSCLC | II | Nivolumab Ipilimumab | 88 | Nivolumab ± Ipilimumab + SRS or WBRT | USA | M.D. Anderson Cancer Center | 2016–2023 |
| NCT 02978404 | NSCLC RCC | II | Nivolumab | 60 | Nivolumab + SRS | Canada | University of Montreal Health Centre | 2017–2023 |
| NCT 03340129 | Melanoma | II | Nivolumab Ipilimumab | 218 | Nivolumab + Ipilimumab ± SRS | Australia | Melanoma Institute Australia | 2017–2025 |
| NCT 03955198 | Melanoma | II | Durvalumab | 100 | Radiotherapy ± Durvalumab | France | Institut Claudius Regaud | 2021–2025 |
| NCT 03175432 | Melanoma | II | Atezolizumab bevacizumab | 60 | Atezolizumab + Bevacizumab ± Cobimetinib | USA | M.D. Anderson Cancer Center | 2017–2023 |
| NCT 03873818 | Melanoma | I | Ipilimumab Pembrolizumab | 30 | Ipilimumab + Pembrolizumab |
USA | M.D. Anderson Cancer Center | 2019–2023 |
| NCT 03696030 | Breast Cancer |
I | / | 39 | HER2-CAR T cells | USA | City of Hope Medical Center | 2018–2023 |
| NCT 02442297 | Breast Cancer |
I | / | 28 | HER2-specific T cells | USA | Baylor College of Medicine | 2016–2036 |
| NCT 03449238 | Breast Cancer |
I/II | Pembrolizumab | 41 | Pembrolizumab + SRS | USA | Weill Medical College of Cornell University | 2018–2026 |